| Autor: |
Razina TV; Sechenov First Moscow State Medical University (Sechenov University)., Serova MV; Sechenov First Moscow State Medical University (Sechenov University).; Pirogov City Clinical Hospital №1 Moscow., Andreev DA; Sechenov First Moscow State Medical University (Sechenov University)., Sazonova YS; Pirogov City Clinical Hospital №1 Moscow., Komarova AG; Botkin City Clinical Hospital Moscow. |
| Jazyk: |
ruština |
| Zdroj: |
Terapevticheskii arkhiv [Ter Arkh] 2023 May 31; Vol. 95 (4), pp. 472054. Date of Electronic Publication: 2023 May 31. |
| DOI: |
10.26442/00403660.2023.04.202189 |
| Abstrakt: |
Screening for atrial fibrillation (AF) has attracted considerable attention recently. Of special interest are patients with cardiac implantable electronic devices (CIEDs) that allow for recording episodes of atrial arrhythmias of various durations, including asymptomatic ones, in which case they are referred to as subclinical atrial fibrillation (SCAF). The available data suggest that the risk of thromboembolic events varies between patients with SCAF and clinically overt AF. As of today, the question regarding anticoagulant therapy in patients with SCAF remains unresolved. The article presents an overview of previous and ongoing studies on this issue, as well as current guidelines on anticoagulant use in patients with SCAF and CIEDs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
